Xenon Pharmaceuticals Inc. (XENE) is a Biotechnology company in the Healthcare sector, currently trading at $59.35. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is XENE = $77 (+29.2% upside).
Valuation: XENE trades at a trailing Price-to-Earnings (P/E) of -13.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 4.61.
Financials: revenue is $8M, -100%/yr average growth. Net income is $346M (loss), growing at -40.5%/yr. Net profit margin is -4612.1% (negative). Gross margin is 66.1% (+1087.2 pp trend).
Balance sheet: total debt is $8M against $582M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 13.42 (strong liquidity). Debt-to-assets is 0.8%. Total assets: $982M.
Analyst outlook: 22 / 22 analysts rate XENE as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 44/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 62/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
